Join the BioCopy team

Role and key responsibilities

• The CEO will be the Managing Director of BioCopy GmbH. She/he will primarily shape the strategic direction of the company and lead the identification of the most promising business opportunities, based upon the proprietary technology of BioCopy.
• She/he will ensure outreach and partnering activities to attract industry partners who can utilize the BioCopy technology to further their R&D projects, thereby creating sustainable value for the company. Simultaneously, she/he will be responsible to build the BioCopy business model around the identification and development of fully owned lead candidates in attractive market segments. 
• She/he will further develop the team, identify resource and capability gaps and close them through training, hiring and contracting as needed. She/he will create and control projects with regards to timelines, quality, costs and risks. 
• The CEO will, in collaboration with the founders, lead the fundraising activities and gain the confidence of current and future investors. The CEO will be a key spokesperson of BioCopy with respect to external audiences like professional organizations, industry partners and Media.
• She/he will also be a member of the governing board of BioCopy AG, the parent company of BioCopy GmbH. Together with the board, the CEO will ensure to complete the transformation of the company from a university spin-off into an integrated biotech company with a portfolio of attractive and innovative products and services, ultimately capturing the upside potential inherent in the proprietary technology for patients, investors and team members. 

Background and experience

• The ideal candidate will be seasoned senior executive with extensive experience in the industry, preferably as CEO or COO. She/he will have a track record of leading young biotech enterprises and transitioning them into mature businesses, and/or preparing their successful exit. 
• Big Pharma experience including Licensing & Partnering will be beneficial to prepare an attractive partnering strategy. Having successfully completed fundraising with private, strategic and/or institutional investors is strongly desired. 
• Ideally the candidate has a strong medical life-sciences academic and/or professional background and gained disease area expertise in one or more of the following areas: immunology, T-cell therapies, oncology. 
• Strong leadership and communication skills and a positive, winning attitude are expected. She/he will be a team player, coaching and delegating yet hands-on when necessary. The CEO will build and expand a high performing team at the company facility close to Freiburg. 
• She/he is equally comfortable and effective working with executives and board members, investors, high intellect scientists. Experience to interact with administrations like FDA and EMA are beneficial. 

Compensation and location

The position will be competitively compensated with a package reflecting the scope of the job and the profile of the candidate, comprising different elements like base salary, achievement-driven bonus payments and equity allocation.

Regular presence at the BioCopy offices close to Freiburg is expected. Partially remote working arrangements will be an option.

Application and Details

Please contact Dr. Günter Roth, CEO for more details: guenter.roth@biocopy.de

About us

BioCopy started as a spin-off from the University Freiburg, Germany. Today, BioCopy AG is a multinational company headquartered in Switzerland, with a fully owned GmbH in Germany, which is running a modern, mid-sized operational unit focusing on R&D in the vicinity of Freiburg. Its large patent portfolio centers on high-throughput, label-free molecular interaction analyses with a broad application spectrum, but an explicit focus on the characterization of therapeutic molecules / candidates (TCRs / TCR-like antibodies) for T-cell based cancer drug development. 
 
BioCopy high-throughput technology can streamline TCR(m)-based drug discovery and ensure informed decisions about the ideal lead candidate based on a wealth of high-quality data that was previously unattainable. This advantage will be exploited for both in-house (drug) development and in collaborations.

The BioCopy team consists of experts in biology, physics, engineering, microsystems technology and business application. Together, they are working towards an improved and faster selection of immune-therapeutics in oncology, with higher efficacy, broader pharmaceutical window and less off-target effects.

Funding is realized to secure operations well into 2025, additional fund raising is ongoing to finance the execution of the business strategy. Several strategic partnerships are envisaged to validate and leverage the platform nature of the underlying IP-protected technology, while progressing to identify and develop own therapeutic assets.